日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

在慢性淋巴细胞白血病(CLL)患者中,将乌布拉利西布和乌布利妥昔单抗(U2)加入伊布替尼治疗方案中:一项基于微小残留病灶(MRD)的II期研究

Roeker, Lindsey E; Feldman, Tatyana A; Soumerai, Jacob D; Falco, Victoria; Panton, Gail; Dorsey, Colleen; Zelenetz, Andrew D; Falchi, Lorenzo; Park, Jae H; Straus, David J; Pena Velasquez, Camila; Lebowitz, Sonia; Fox, Yehudit; Battiato, Kristen; Laudati, Carissa; Thompson, Meghan C; McCarthy, Elizabeth; Kdiry, Sabrina; Martignetti, Rosalba; Turpuseema, Teja; Purdom, Michelle; Paskalis, Dana; Miskin, Hari P; Sportelli, Peter; Leslie, Lori A; Mato, Anthony R

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

在首次复发/原发性难治性弥漫性大B细胞淋巴瘤中,利妥昔单抗、异环磷酰胺、卡铂、依托泊苷(RICER)方案中加入来那度胺

Feldman, Tatyana; Mato, Anthony R; Chow, Kar F; Protomastro, Ewelina A; Yannotti, Kara M L; Bhattacharyya, Pritish; Yang, Xiao; Donato, Michele L; Rowley, Scott D; Carini, Carolanne; Valentinetti, Marisa; Smith, Judith; Gadaleta, Gabriella; Bejot, Coleen; Stives, Susan; Timberg, Mary; Kdiry, Sabrina; Pecora, Andrew L; Beaven, Anne W; Goy, Andre